Pictet Asset Management Sa Revance Therapeutics, Inc. Transaction History
Pictet Asset Management Sa
- $83.4 Billion
- Q2 2023
A detailed history of Pictet Asset Management Sa transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Pictet Asset Management Sa holds 8,991 shares of RVNC stock, worth $23,106. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,991
Previous 11,770
23.61%
Holding current value
$23,106
Previous $379,000
40.11%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RVNC
# of Institutions
21Shares Held
10.1MCall Options Held
360KPut Options Held
0-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL423KShares$1.09 Million0.0% of portfolio
-
Rothschild & CO Asset Management Us Inc. New York, NY370KShares$949,9950.1% of portfolio
-
International Biotechnology Trust PLC London, X0289KShares$742,0251.12% of portfolio
-
Credit Suisse Ag Zurich, V8180KShares$462,9800.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...